Loading
A phase 3 trial of Glasdegib, CPX-351, Azacitidine and Cytarabine in Leukaemia, run by Pfizer, completed.
A Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib In Patients With Previously Untreated Acute Myeloid Leukemia is a phase 3 interventional study registered as NCT03416179 by Pfizer, with 730 participants recorded, started 2018-04-20 and reaching its primary completion in 2020-06-05. Interventions recorded: glasdegib, daunorubicin + cytarabine, azacitidine, Placebo, Placebo, glasdegib, cytarabine, HSCT. Conditions recorded: Leukemia, Myeloid, Acute.
Linked to the drug Glasdegib because the registry names it among its interventions and Leukaemia among its conditions. Registry record only: no result has been read by an editor.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
730 enrolled.
95% CI 15.2 to 18.5; Figures from the ClinicalTrials.gov results section (first posted 2021-06-25), not from a publication · 95% CI 17.6 to NA
Source95% CI 7.7 to 12.4; Figures from the ClinicalTrials.gov results section (first posted 2021-06-25), not from a publication · 95% CI 8.4 to 13.3
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Intensive Study: Overall Survival (OS)primary | Intensive Study: Glasdegib + Cytarabine + Daunorubicin | 201 | 17.3 months | 1.08 (0.755 to 1.532) | 0.6579 | link |
| Intensive Study: Placebo + Cytarabine + Daunorubicin | 203 | 20.4 months | ||||
| Non-intensive Study: Overall Survival (OS)primary | Non-intensive Study: Glasdegib + Azacitidine | 163 | 10.3 months | 1.04 (0.775 to 1.388) | 0.5955 | link |
| Non-intensive Study: Placebo + Azacitidine | 162 | 10.6 months |
Shares Glasdegib, Azacitidine, Pfizer (incl. Seagen), Leukaemia (all types) and the tag pipeline.
Shares Glasdegib and the tag pipeline.
Shares Azacitidine, Leukaemia (all types) and the tag pipeline.
Shares Azacitidine, Leukaemia (all types) and the tag pipeline.
Shares Cytarabine, Leukaemia (all types) and the tag pipeline.
Shares Cytarabine, Azacitidine and the tag pipeline.
Shares Cytarabine, Azacitidine and the tag pipeline.
Shares Cytarabine, Azacitidine and the tag pipeline.